multiple sclerosis
Multiple sclerosis studies underway using existing drugs
April 2, 2015Research and Development, Sales and Marketing MS, Midamor, Prozac, Rilutek, Sanofi, amiloride, covis, fluoxetine, multiple sclerosis, riluzole
Three existing drugs that fight heart disease, depression and motor neurone disease could be used to treat multiple sclerosis (MS) …
Mixed results for Biogen’s MS drug
January 9, 2015Sales and Marketing Anti-LINGO-1, BIIB033, Biogen IDEC, MS, multiple sclerosis, plegridy
An experimental drug from Biogen Idec for the treatment of multiple sclerosis (MS) has shown a mixed bag of results …
Teva launches new MS eHealth site
September 4, 2014Medical Communications, Sales and Marketing Teva, digital, ms ireland, multiple sclerosis, pow health
Teva and MS Ireland have helped launch a new website called Pow Health to give multiple sclerosis patients a “one-stop …
Roche to launch new MS collaboration
June 23, 2014Research and Development, Sales and Marketing MS, Roche, inception sciences, multiple sclerosis, versant ventures
Roche has launched a new research collaboration to investigate ways of reversing the debilitating nerve damage caused by multiple sclerosis …
Genzyme MS drug approved in US
September 13, 2012Medical Communications Aubagio, Genzyme, Rebif, Sanofi, Tysabri, gilenya, multiple sclerosis
US regulators have given the green light for Genzyme’s Aubagio to treat patients with relapsing forms of multiple sclerosis (MS). …
Genzyme ‘confident’ of FDA nod for MS drug
August 29, 2012Sales and Marketing Genzyme, Lemtrada, MS, multiple sclerosis
Genzyme insists it is on course to resubmit an existing oncology drug for the treatment of relapsing multiple sclerosis (RMS), …
Elan to spin off drug discovery arm
August 14, 2012Research and Development, Sales and Marketing Elan, Neotype Biosciences, Tysabri, multiple sclerosis
Elan Corporation is to spin off its drug discovery arm Neotype Biosciences to create a separate, quoted company by the …
MS audit finds little improvement in care
October 12, 2011MS, multiple sclerosis
There has been “little or no improvement” in the care of multiple sclerosis patients over the past five years, according …
Study shows new genetic risk factors for MS
August 15, 2011Research and Development genes, multiple sclerosis, research and development news
New genetic links to the immune system have been identified as a possible trigger for multiple sclerosis. The exact causes …
Merck scraps MS pill cladribine
June 23, 2011Research and Development, Sales and Marketing Cladribine, Merck KGaA, Movectro, multiple sclerosis
Merck KGaA has pulled all pending applications for its multiple sclerosis pill Movectro and will withdraw it from the markets …
Oral MS drug Gilenya launched in the UK
April 19, 2011Sales and Marketing Novartis, gilenya, multiple sclerosis
Gilenya has become the first oral multiple sclerosis drug to be launched in the UK. Gilenya (fingolimod) is licenced to …
First oral MS pill approved in Europe
March 21, 2011Sales and Marketing MS, Novaris, fingolimod, first oral multiple sclerosis drug, gilenya, multiple sclerosis
Novartis’ Gilenya has become the first oral multiple sclerosis drug to be approved in Europe. Gilenya (fingolimod) is now licensed …
FDA knocks back Merck KGaA’s oral MS drug
March 2, 2011Sales and Marketing Cladribine, EMD Serono, FDA, MS, Merck KGaA, Movectro, multiple sclerosis, oral MS drugs
US authorities have turned down Merck KGaA’s new drug application for its oral relapsing-remitting multiple sclerosis treatment Movectro. The FDA …
Digital Pharma: Merck Serono sets up MS social network
February 18, 2011Medical Communications Digital Pharma blog, MS, Merck Serono, Movectro, Rebif, multiple sclerosis, social networking
Merck Serono has set up an international social network for multiple sclerosis patients, saying today’s pharma companies should go beyond …
Merck Serono halts Movectro European licence application
February 18, 2011Medical Communications, Sales and Marketing Cladribine, MS, Merck KGaA, Merck Serono, Movectro, fingolimod, gilenya, multiple sclerosis
Merck Serono has withdrawn its European licence application for multiple sclerosis drug Movectro. Movectro (cladribine) is a new oral treatment …
Latest content
Jager-van Dijk is new Arletta Pharma Solutions CEO
Tridem begins phase Ib trial of Parkinson’s disease vaccine
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
